Eribulin mesylate injection Clinical Trials

3 actively recruiting trials

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1

Indications

Breast Cancer3
Cancer3
Recurrent Breast Cancer1
HRD-positive/HER2-negative Advanced Breast Cancer1
Fludzoparib" and Anti-angiogenic1

Other3 trials

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.